Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review

• Main Authors: Mark T. Reding (Author), Shadan Lalezari (Author), Gili Kenet (Author), Giovanni Di Minno (Author), Jonathan Ducore (Author), Alexander Solms (Author), Anita Shah (Author), Pål André Holme (Author), Lone H. Poulsen (Author), Karina Meijer (Author), Mindy Simpson (Author), Maria Elisa Mancuso (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Damoctocog alfa pegol (BAY 94-9027, Jivi®), is a site-specifically PEGylated, extended half-life recombinant factor VIII (FVIII) that is approved in several European and non-European countries for on-demand treatment and prophylaxis of bleeding in previously treated patients aged ≥ 12 year...